TO COMPARE THE EFFECT OF ABHAYADI GHANAWATI AND TABLET RANITIDINE IN MANAGEMENT OF URDHVAG AMLAPITTA
Phase 1
- Conditions
- Health Condition 1: K00-K95- Diseases of the digestive system
- Registration Number
- CTRI/2019/06/019824
- Lead Sponsor
- PDEA COLLEGE OF AYURVEDA AND RESEARCH CENTRE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
PATIENTS HAVING SIGNS AND SYMPTOMS OF URDHVAG AMLAPITTA
Exclusion Criteria
1.PATIENTS SUFFERING FROM GASTRIC AND DUODENAL ULCERS
2.IMMUNOCOMPRAMISED PATIENTS,BLOOD COAGULATION.
3.PREGNANT AND LACTATING WOMEN
4.CA-STOMACH, ESOPHAGUS, ESOPHAGEAL VARICES,HEMATEMESIS
5.PATIENTS HAVING HEPATIC AND RENAL DISORDERS
6.MAJOR SYSTEMIC DISEASES LIKE HTN, DM,TB
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ABHAYADI GHANAWATI 500MG 1 TAB TWICE A DAY IN MANAGEMENT OF URDHVAG AMLAPITTA FOR 30 DAYSTimepoint: ABHAYADI GHANAWATI 500MG 1 TAB TWICE A DAY IN MANAGEMENT OF URDHVAG AMLAPITTA FOR 30 DAYS
- Secondary Outcome Measures
Name Time Method TO ASSESS THE EFFICACY OF TAB.RANITIDINE IN MANAGEMENT OF URDHVAG AMLAPITTATimepoint: TO ASSESS THE EFFICACY OF ABHAYADI GHANAWATI IN THE MANAGEMENT OF URDHVAG AMLAPITTA FOR DURATION OF 30 DAYS